AI Analysis
AI-generated analysis. Always verify with the original filing.
Adlai Nortye Ltd. announced that the first patient was dosed in the United States in early February 2026 in its ongoing global Phase 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor for advanced or metastatic solid tumors harboring RAS mutations. The trial is conducted in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd., with Adlai Nortye retaining ex-China rights.
Key Takeaways
1First patient dosed in U.S. in early February 2026 in Phase 1 trial of AN9025
2AN9025 is an oral pan-RAS (ON) inhibitor for solid tumors with RAS mutations
3Trial is first-in-human, multicenter, open-label evaluating safety, tolerability, PK, and anti-tumor activity
4Collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm)
5Adlai Nortye retains ex-China rights; ASK Pharm holds rights in mainland China, Hong Kong, Macao
6Quote from Dr. Archie Tse, Head of R&D, on milestone and strategy